The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Lipid-based nanoparticle technologies for liver targeting
Abstract
Liver diseases such as hepatitis, cirrhosis, and hepatocellular carcinoma are global health problems accounting for approximately 800 million cases and over 2 million deaths per year worldwide. Major drawbacks of standard pharmacological therapies are the inability to deliver a sufficient concentration of a therapeutic agent to the diseased liver, and nonspecific drug delivery leading to undesirable systemic side effects. Additionally, depending on the specific liver disease, drug delivery to a subset of liver cells is required. In recent years, lipid nanoparticles have been developed to passively and actively target drugs to the liver. The success of this approach has been highlighted by the FDA-approval of the first liver-targeting lipid nanoparticle, ONPATTRO, in 2018, and many other promising candidate technologies are expected to follow. This review summarizes recent developments of various lipid-based liver-targeting technologies, namely solid-lipid nanoparticles, liposomes, niosomes and micelles, and discusses the challenges and future perspectives in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
(1989) · PubMed · Cited by 3,343
Hepatitis B Virus Infection — Natural History and Clinical Consequences
Ganem, D., & Prince, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031087 · Cited by 2,357
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
CURCUMIN: THE INDIAN SOLID GOLD
Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_1 · Cited by 1,647
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Self-citationTrefts, E., Gannon, M., & Wasserman, D. H. (2017) · Current Biology · doi:10.1016/j.cub.2017.09.019 · Cited by 1,452
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J.-L., Kim, T.-Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 975
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Blouin, A., Bolender, R. P., & Weibel, E. R. (1977) · The Journal of cell biology · doi:10.1083/jcb.72.2.441 · Cited by 859
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Wisse, E., de Zanger, R. B., Charels, K., van der Smissen, P., & McCuskey, R. S. (1985) · Hepatology · doi:10.1002/hep.1840050427 · Cited by 712
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Kulkarni, J. A., Darjuan, M. M., Mercer, J. E., Chen, S., van der Meel, R., Thewalt, J. L., Tam, Y. Y. C., & Cullis, P. R. (2018) · ACS Nano · doi:10.1021/acsnano.8b01516 · Cited by 663
Nonionic surfactant vesicular systems for effective drug delivery—an overview
Kumar, G. P., & Rajeshwarrao, P. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.09.002 · Cited by 644
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease
(2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5 · Cited by 638
Niosome: A future of targeted drug delivery systems
Kuotsu, K., Karim, K., Mandal, A., Biswas, N., Guha, A., Chatterjee, S., & Behera, M. (2010) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/0110-5558.76435 · Cited by 626
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
D'Souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 621
Hepatology. A Textbook of Liver Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-259_2 · Cited by 621
Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 609
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
Inorganic Nanoparticles as Carriers of Nucleic Acids into Cells
Sokolova, V., & Epple, M. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200703039 · Cited by 581
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.
Brown, M. S., & Goldstein, J. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111044 · Cited by 545
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513
Marcellin, P., & Kutala, B. K. (2018) · Liver International · doi:10.1111/liv.13682 · Cited by 513
Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
The asialoglycoprotein receptor: a model for endocytic transport receptors
Spiess, M. (1990) · Biochemistry · doi:10.1021/bi00495a001 · Cited by 485
The preparation and properties of niosomes—non-ionic surfactant vesicles
Baillie, A. J., Florence, A. T., Hume, L. R., Muirhead, G. T., & Rogerson, A. (1985) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1985.tb04990.x · Cited by 473
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.008 · Cited by 470
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Hepatic Stellate Cells and Liver Fibrosis
Moreira, R. K. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1728-hscalf · Cited by 452
Schulze, A., Gripon, P., & Urban, S. (2007) · Hepatology · doi:10.1002/hep.21896 · Cited by 445
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00166 · Cited by 390
Lactoferrin: Molecular structure, binding properties and dynamics of lactoferrin
Baker, E. N., & Baker, H. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5368-9 · Cited by 387
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Abdelkader, H., Alani, A. W. G., & Alany, R. G. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838077 · Cited by 341
Maeng, J. H., Lee, D.-H., Jung, K. H., Bae, Y.-H., Park, I.-S., Jeong, S., Jeon, Y.-S., Shim, C.-K., Kim, W., Kim, J., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.068 · Cited by 333
Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M. (2018) · Small Methods · doi:10.1002/smtd.201700375 · Cited by 332
Gubernator, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.566552 · Cited by 325
The global burden of liver disease: a challenge for methods and for public health
Byass, P. (2014) · BMC Medicine · doi:10.1186/s12916-014-0159-5 · Cited by 321
Maeki, M., Kimura, N., Sato, Y., Harashima, H., & Tokeshi, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.008 · Cited by 319
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging
Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X., & Low, P. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601455103 · Cited by 318
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.009 · Cited by 309
Li, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Göppert, T. M., & Müller, R. H. (2005) · Journal of Drug Targeting · doi:10.1080/10611860500071292 · Cited by 299
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizón, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., & Zalipsky, S. (2003) · PubMed · Cited by 295
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
Influence of Cholesterol on the Association of Plasma Proteins with Liposomes
Semple, S. C., Chonn, A., & Cullis, P. R. (1996) · Biochemistry · doi:10.1021/bi950414i · Cited by 291
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Fenton, O. S., Kauffman, K. J., Kaczmarek, J. C., McClellan, R. L., Jhunjhunwala, S., Tibbitt, M. W., Zeng, M. D., Appel, E. A., Dorkin, J. R., Mir, F. F., et al. (2017) · Advanced Materials · doi:10.1002/adma.201606944 · Cited by 288
Nanotechnology applied to the treatment of malaria
Santos-Magalhães, N. S., & Mosqueira, V. C. F. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.024 · Cited by 286
Adlerova, L., Bartoskova, A., & Faldyna, M. (2008) · Veterinární medicína · doi:10.17221/1978-vetmed · Cited by 280
Hepatic stellate cells: a target for the treatment of liver fibrosis
Wu, J., & Zern, M. A. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070045 · Cited by 273
Roles of lipid polymorphism in intracellular delivery
Hafez, I. M., & Cullis, P. R. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00103-x · Cited by 266
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery
Fenton, O. S., Kauffman, K. J., McClellan, R. L., Appel, E. A., Dorkin, J. R., Tibbitt, M. W., Heartlein, M. W., DeRosa, F., Langer, R., & Anderson, D. G. (2016) · Advanced Materials · doi:10.1002/adma.201505822 · Cited by 252
Nanoparticles for the delivery of genes and drugs to human hepatocytes
Yamada, T., Iwasaki, Y., Tada, H., Iwabuki, H., Chuah, M. K., VandenDriessche, T., Fukuda, H., Kondo, A., Ueda, M., Seno, M., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt843 · Cited by 247
Campbell, F., Bos, F. L., Sieber, S., Arias-Alpizar, G., Koch, B. E., Huwyler, J., Kros, A., & Bussmann, J. (2018) · ACS Nano · doi:10.1021/acsnano.7b06995 · Cited by 233
Lyon, P. C., Gray, M. D., Mannaris, C., Folkes, L. K., Stratford, M., Campo, L., Chung, D. Y. F., Scott, S., Anderson, M., Goldin, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30332-2 · Cited by 233
Maurer, N., Wong, K. F., Stark, H., Louie, L., McIntosh, D., Wong, T., Scherrer, P., Semple, S. C., & Cullis, P. R. (2001) · Biophysical Journal · doi:10.1016/s0006-3495(01)76202-9 · Cited by 232
Rensen, P. C. N., Sliedregt, L. A. J. M., Ferns, M., Kieviet, E., van Rossenberg, S. M. W., van Leeuwen, S. H., van Berkel, T. J. C., & Biessen, E. A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101786200 · Cited by 231
Alyautdin, R. N., Tezikov, E. B., Ramge, P., Kharkevich, D. A., Begley, D. J., & Kreuter, J. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006836 · Cited by 229
Review article: the management of hepatocellular carcinoma
CABRERA, R., & NELSON, D. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04200.x · Cited by 222
Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain
Sun, W., Xie, C., Wang, H., & Hu, Y. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.09.087 · Cited by 215
Glucose-6-Phosphate Dehydrogenase Deficiency and Antimalarial Drug Development
Beutler, E., Duparc, S., & _, _. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.779 · Cited by 215
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
Dou, Y., Hynynen, K., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.025 · Cited by 210
Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS
James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., & Stewart, J. S. W. (1994) · Clinical Oncology · doi:10.1016/s0936-6555(05)80269-9 · Cited by 205
Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats
Lekgabe, E. D., Kiriazis, H., Zhao, C., Xu, Q., Moore, X. L., Su, Y., Bathgate, R. A. D., Du, X.-J., & Samuel, C. S. (2005) · Hypertension · doi:10.1161/01.hyp.0000171930.00697.2f · Cited by 203
Low Molecular Weight Disulfide Cross-Linking Peptides as Nonviral Gene Delivery Carriers
McKenzie, D. L., Smiley, E., Kwok, K. Y., & Rice, K. G. (2000) · Bioconjugate Chemistry · doi:10.1021/bc000056i · Cited by 200
Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions
Elsabahy, M., Nazarali, A., & Foldvari, M. (2011) · Current Drug Delivery · doi:10.2174/156720111795256174 · Cited by 199
Efficient Oncogene Silencing and Metastasis Inhibition via Systemic Delivery of siRNA
Li, S.-D., Chono, S., & Huang, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.51 · Cited by 198
Self-citationNatural History and Clinical Consequences of Hepatitis B Virus Infection
Pan, C. Q., & Zhang, J. X. (2005) · International Journal of Medical Sciences · doi:10.7150/ijms.2.36 · Cited by 197
Thermoresponsive core–shell magnetic nanoparticles for combined modalities of cancer therapy
Purushotham, S., Chang, P. E. J., Rumpel, H., Kee, I. H. C., Ng, R. T. H., Chow, P. K. H., Tan, C. K., & Ramanujan, R. V. (2009) · Nanotechnology · doi:10.1088/0957-4484/20/30/305101 · Cited by 197
Hepatocellular carcinoma: A comprehensive review
Waller, L. P. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i26.2648 · Cited by 196
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
(1994) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068903 · Cited by 195
Lipid nanoparticle delivery systems for siRNA-based therapeutics
Wan, C., Allen, T. M., & Cullis, P. R. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 193
Augmented liver targeting of exosomes by surface modification with cationized pullulan
Tamura, R., Uemoto, S., & Tabata, Y. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.013 · Cited by 186
Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery
Khalil, I. A., Kogure, K., Futaki, S., Hama, S., Akita, H., Ueno, M., Kishida, H., Kudoh, M., Mishina, Y., Kataoka, K., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302910 · Cited by 178
Reversal of liver fibrosis: From fiction to reality
Zoubek, M. E., Trautwein, C., & Strnad, P. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.04.005 · Cited by 174
Diagnostic imaging and therapeutic application of nanoparticles targeting the liver
Wang, H., Thorling, C. A., Liang, X., Bridle, K. R., Grice, J. E., Zhu, Y., Crawford, D. H. G., Xu, Z. P., Liu, X., & Roberts, M. S. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01611d · Cited by 173
Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I
Kim, S. I., Shin, D., Choi, T. H., Lee, J. C., Cheon, G.-J., Kim, K.-Y., Park, M., & Kim, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300168 · Cited by 169
Joshi, M., Pathak, S., Sharma, S., & Patravale, V. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.032 · Cited by 168
Tak, W. Y., Lin, S.-M., Wang, Y., Zheng, J., Vecchione, A., Park, S. Y., Chen, M. H., Wong, S., Xu, R., Peng, C.-Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2433 · Cited by 167
Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Rockey, D. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.011 · Cited by 163
Moghimi, S. M., & Hunter, A. C. (2001) · Pharmaceutical Research · doi:10.1023/a:1011054123304 · Cited by 161
Matsusue, R., Kubo, H., Hisamori, S., Okoshi, K., Takagi, H., Hida, K., Nakano, K., Itami, A., Kawada, K., Nagayama, S., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0599-x · Cited by 161
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Leung, A. K. K., Tam, Y. K., & Cullis, P. R. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.025 · Cited by 160
Alnylam launches era of RNAi drugs
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt0918-777 · Cited by 157
Delivery of liposome-encapsulated drugs to macrophages
Alving, C. R. (1983) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(83)90010-4 · Cited by 149
Jiang, H., Kwon, J., Kim, E., Kim, Y.-K., Arote, R. B., Jere, D., Jeong, H., Jang, M.-K., Nah, J., Xu, C., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.029 · Cited by 147
Beljaars, L., Molema, G., Schuppan, D., Geerts, A. E., Bleser, P. J. D., Weert, B., Meijer, D. K. F., & Poelstra, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12743 · Cited by 146
Nanotechnology for therapy and imaging of liver diseases
Reddy, L. H., & Couvreur, P. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.039 · Cited by 145
Gao, D.-Y., Lin, T.-T., Sung, Y., Liu, Y. C., Chiang, W., Chang, C.-C., Liu, J., & Chen, Y. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.035 · Cited by 144
LDL receptor relatives at the crossroad of endocytosis and signaling
Schneider, W. J., & Nimpf, J. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2183-z · Cited by 142
Lipid-based amphotericin B: a review of the last 10 years of use
Hann, I. M., & Prentice, H. G. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00341-1 · Cited by 137
Anti‐fibrotic actions of relaxin
Samuel, C. S., Royce, S. G., Hewitson, T. D., Denton, K. M., Cooney, T., & Bennett, R. G. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13529 · Cited by 137
Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy
Hu, M., Wang, Y., Xu, L., An, S., Tang, Y., Zhou, X., Li, J., Liu, R., & Huang, L. (2019) · Nature Communications · doi:10.1038/s41467-019-10893-8 · Cited by 135
Moreno, M., Gonzalo, T., Kok, R. J., Sancho‐Bru, P., van Beuge, M. M., Swart, J., Prakash, J., Temming, K., Fondevila, C., Beljaars, L., et al. (2009) · Hepatology · doi:10.1002/hep.23419 · Cited by 134
Amphotericin B lipid preparations: what are the differences?
Adler‐Moore, J., & Proffitt, R. T. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01979.x · Cited by 132
Wood, B. J., Poon, R. T. P., Locklin, J. K., Dreher, M. R., Ng, K. K., Eugeni, M. A., Seidel, G., Dromi, S. A., Neeman, Z., Kolf, M., et al. (2011) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2011.10.018 · Cited by 132
The Role of Liver Sinusoidal Cells in Hepatocyte-Directed Gene Transfer
Jacobs, F., Wisse, E., & Geest, B. D. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090136 · Cited by 132
Chang, J., Chen, X., Glass, Z., Gao, F., Mao, L., Wang, M., & Xu, Q. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00493 · Cited by 132
Dika, I. E., Lim, H. Y., Yong, W. P., Lin, C., Yoon, J., Modiano, M., Freilich, B. L., Choi, H. J., Chao, T.-Y., Kelley, R. K., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0838 · Cited by 130
Charge-reversal nanoparticles: novel targeted drug delivery carriers
Chen, X., Liu, L., & Jiang, C. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.011 · Cited by 128
Kamps, J. A. A. M., Morselt, H. W. M., Swart, P. J., Meijer, D. K. F., & Scherphof, G. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11681 · Cited by 127
Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance
Mishra, N., Yadav, N. P., Kumar, V., Sinha, P., Yadav, K. S., Jain, S., & Arora, S. (2013) · BioMed Research International · doi:10.1155/2013/382184 · Cited by 123
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
Pauli, G., Tang, W.-L., & Li, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090465 · Cited by 121
Self-citationCyclic Arg-Gly-Asp Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats
Du, S.-L., Pan, H., Lu, W., Wang, J., Wu, J., & Wang, J.-Y. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122481 · Cited by 120
A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
Warashina, S., Nakamura, T., Sato, Y., Fujiwara, Y., Hyodo, M., Hatakeyama, H., & Harashima, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.042 · Cited by 120
A Highly Efficient Synthetic Vector: Nonhydrodynamic Delivery of DNA to Hepatocyte Nucleiin Vivo
Hu, Y., Haynes, M. T., Wang, Y., Liu, F., & Huang, L. (2013) · ACS Nano · doi:10.1021/nn4012384 · Cited by 119
Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular Carcinoma
Shi, B., Abrams, M. T., & Sepp‐Lorenzino, L. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413503662 · Cited by 119
Hepatology: A Textbook of Liver Disease.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-816_10 · Cited by 119
Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes
Bao, Y., Jin, Y., Chivukula, P., Zhang, J., Liu, Y., Liu, J., Clamme, J., Mahato, R. I., Ng, D., Ying, W., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0874-6 · Cited by 118
Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases
Li, L., Wang, H., Ong, Z. Y., Xu, K., Ee, P. L. R., Zheng, S., Hedrick, J. L., & Yang, Y. Y. (2010) · Nano Today · doi:10.1016/j.nantod.2010.06.007 · Cited by 115
Chen, J., Wu, H., Deyan, H., & Xie, C. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.024 · Cited by 114
Reebye, V., Huang, K., Lin, V., Jarvis, S., Cutillas, P. R., Dorman, S., Ciriello, S., Andrikakou, P., Voutila, J., Sætrom, P., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0126-2 · Cited by 109
Samaniego, R., Palacios, B. S., Domínguez‐Soto, Á., Vidal, C., Salas, A., Matsuyama, T., Sánchez‐Torres, C., de la Torre, I., Miranda‐Carús, M., Sánchez‐Mateos, P., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613345 · Cited by 106
Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis
Chen, Z., Jain, A., Liu, H., Zhao, Z., & Cheng, K. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.256156 · Cited by 106
Borkham‐Kamphorst, E., Kovalenko, E., van Roeyen, C. R. C., Gaßler, N., Bomble, M., Ostendorf, T., Floege, J., Gressner, A. M., & Weiskirchen, R. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.71 · Cited by 105
Sato, Y., Matsui, H., Yamamoto, N., Sato, R., Munakata, T., Kohara, M., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.044 · Cited by 105
Beljaars, L., Weert, B., Geerts, A. E., Meijer, D. K. F., & Poelstra, K. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00445-3 · Cited by 103
Protein Adsorption: A Feasible Method for Nanoparticle Functionalization?
Cagliani, R., Gatto, F., & Bardi, G. (2019) · Materials · doi:10.3390/ma12121991 · Cited by 102
Drug shortages–a critical challenge for the generic-drug market
Chabner, B. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1112633 · Cited by 99
Oh, H., Jo, H.-Y., Park, J. S., Kim, D., Cho, J., Kim, P., & Kim, K. (2016) · Nanomaterials · doi:10.3390/nano6080141 · Cited by 97
Fallowfield, J. A., Hayden, A. L., Snowdon, V., Aucott, R. L., Stutchfield, B. M., Mole, D. J., Pellicoro, A., Gordon‐Walker, T. T., Henke, A., Schrader, J., et al. (2013) · Hepatology · doi:10.1002/hep.26627 · Cited by 96
Cyclic RGD Functionalized Gold Nanoparticles for Tumor Targeting
Arosio, D., Manzoni, L., Araldi, E. M. V., & Scolastico, C. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100448r · Cited by 96
Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer Cells
Chen, Y., Sen, J., Bathula, S. R., Yang, Q., Fittipaldi, R., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800136v · Cited by 96
Nanotechnology applications for the therapy of liver fibrosis
Giannitrapani, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7242 · Cited by 93
Haltiwanger, R. S., Lehrman, M. A., Eckhardt, A. E., & Hill, R. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38410-7 · Cited by 92
Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery
He, Z., Zheng, X. E., Wu, X. H., Song, X. R., He, G., Wu, W. F., Yu, S., Mao, S. J., & Wei, Y. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.06.029 · Cited by 92
Iodinated α-tocopherol nano-emulsions as non-toxic contrast agents for preclinical X-ray imaging
Li, X., Anton, N., Zuber, G., Zhao, M., Messaddeq, N., Hallouard, F., Fessi, H., & Vandamme, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.026 · Cited by 92
Tang, J., Wang, Q., Yu, Q., Qiu, Y., Mei, L., Wan, D., Wang, X., Li, M., & He, Q. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.11.002 · Cited by 92
On the mechanism of hepatic transendothelial passage of large liposomes
Romero, E. L., Morilla, M. J., Regts, J., Koning, G. A., & Scherphof, G. L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00364-6 · Cited by 91
Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery
Wang, Q., Zhang, L., Hu, W., Hu, Z., Bei, Y.-Y., Xu, J.-Y., Wang, W., Zhang, X.-N., & Zhang, Q. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.07.006 · Cited by 91
Tang, W.-L., Tang, W.-H., Szeitz, A. J., Kulkarni, J. A., Cullis, P. R., & Li, S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.004 · Cited by 90
Self-citationSuccessful imaging of human cancer with indium-111-labeled phospholipid vesicles
Presant, C. A., Proffitt, R. T., Turner, A., Williams, L. E., Winsor, D. T., Werner, J. L., Kennedy, P., Wiseman, C. L., Gala, K. V., McKenna, R. J., et al. (1988) · Cancer · Cited by 89
Oxymatrine liposome attenuates hepatic fibrosisviatargeting hepatic stellate cells
Chai, N. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i31.4199 · Cited by 89
Sato, Y., Hatakeyama, H., Hyodo, M., & Harashima, H. (2015) · Molecular Therapy · doi:10.1038/mt.2015.222 · Cited by 88
Snoeys, J., Lievens, J., Wisse, E., Jacobs, F., Duimel, H., Collen, D., Frederik, P. M., & Geest, B. D. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302899 · Cited by 87
Biomaterials in siRNA Delivery: A Comprehensive Review
Ho, W., Zhang, X., & Xu, X. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600418 · Cited by 85
Shimada, K., Kamps, J. A. A. M., Regts, J., Ikeda, K., Shiozawa, T., Hirota, S., & Scherphof, G. L. (1997) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00036-9 · Cited by 84
Fitzgerald, K. A., Malhotra, M., Gooding, M., Sallas, F., Evans, J. C., Darcy, R., & O’Driscoll, C. M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.055 · Cited by 83
Chen, F., Zhang, J., Wang, L., Wang, Y., & Chen, M. (2015) · Nanoscale · doi:10.1039/c5nr04612b · Cited by 81
Li, F., Li, Q., Wang, J., Zhan, C., Xie, C., & Lu, W. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.023 · Cited by 80
Local and transient gene expression primes the liver to resist cancer metastasis
Goodwin, T. J., Zhou, Y., Musetti, S., Liu, R., & Huang, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2306 · Cited by 80
Lehrman, M. A., Haltiwanger, R. S., & Hill, R. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38409-0 · Cited by 79
Maghraby, G. M. E., & Williams, A. C. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802691059 · Cited by 79
Presant, C. A., Blayney, D. W., Kennedy, P., Wiseman, C. L., Gala, K. V., Presant, S., Proffitt, R. T., Crossley, R. J., Preiss, S. J., Ksionski, G., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)91188-g · Cited by 79
Khan, M. A. Q., Wu, V., Ghosh, S., & Uskoković, V. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.03.007 · Cited by 78
Capacity limits of asialoglycoprotein receptor-mediated liver targeting
Bon, C., Höfer, T., Bousquet‐mélou, A., Davies, M. R., & Krippendorff, B. (2017) · mAbs · doi:10.1080/19420862.2017.1373924 · Cited by 77
The sigma-1 receptor: a regulator of cancer cell electrical plasticity?
Crottès, D., Guizouarn, H., Martin, P., Borgèse, F., & Soriani, O. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00175 · Cited by 76
Lehrman, M. A., & Hill, R. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38408-9 · Cited by 73
Xu, Y., Guo, X., Tu, L., Zou, Q., Li, Q., Tang, C., Chen, B., Wu, C., & Wei, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87011 · Cited by 72
Technetium-labelled liposome imaging for deep-seated infection
Morgan, J. R., Williams, L. A., & Howard, C. B. (1985) · British Journal of Radiology · doi:10.1259/0007-1285-58-685-35 · Cited by 72
Nano-sized calcium phosphate (CaP) carriers for non-viral gene deilvery
Lee, D., Upadhye, K. V., & Kumta, P. N. (2011) · Materials Science and Engineering B · doi:10.1016/j.mseb.2011.11.001 · Cited by 69
Riviere, K., Huang, Z. R., Jerger, K., Macaraeg, N., & Szoka, F. C. (2010) · Journal of drug targeting · doi:10.3109/10611861003733953 · Cited by 68
Jia, Z., Gong, Y. Q., Pi, Y., Liu, X., Gao, L., Kang, L., Wang, J., Yang, F., Tang, J., Lu, W., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00709 · Cited by 68
Yamamoto, N., Sato, Y., Munakata, T., Kakuni, M., Tateno, C., Sanada, T., Hirata, Y., Murakami, S., Tanaka, Y., Chayama, K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.014 · Cited by 67
Shobaki, N., Sato, Y., & Harashima, H. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s188016 · Cited by 67
Liver cell-targeted delivery of therapeutic molecules
Kang, J., Toita, R., & Murata, M. (2014) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2014.930017 · Cited by 63
Two PDGF‐B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation.
Clements, J. M., Bawden, L. J., Bloxidge, R. E., Catlin, G., Cook, A. L., Craig, S., Drummond, A. H., Edwards, R. M., Fallon, A., & Green, D. R. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04988.x · Cited by 63
Rohilla, R., Garg, T., Goyal, A. K., & Rath, G. (2014) · Drug Delivery · doi:10.3109/10717544.2014.945018 · Cited by 62
Yang, K. W., Li, X. R., Yang, Z. L., Li, P. Z., Wang, F., & Liu, Y. (2008) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31866 · Cited by 62
Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform
Satterlee, A., & Huang, L. (2016) · Theranostics · doi:10.7150/thno.14689 · Cited by 62
Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers
Opanasopit, P., Sakai, M., Nishikawa, M., Kawakami, S., Yamashita, F., & Hashida, M. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00006-8 · Cited by 61
Greupink, R., Bakker, H. I., Bouma, W., Reker‐Smit, C., Meijer, D. K. F., Beljaars, L., & Poelstra, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099499 · Cited by 60
Abdellatif, A. A. H., Zayed, G., Elbakry, A. M., Zaky, A., Saleem, I. Y., & Tawfeek, H. M. (2016) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2016.1173052 · Cited by 60
Dicetyl Phosphate-Tetraethylenepentamine-Based Liposomes for Systemic siRNA Delivery
Asai, T., Matsushita, S., Kenjo, E., Tsuzuku, T., Yonenaga, N., Koide, H., Hatanaka, K., Dewa, T., Nango, M., Maeda, N., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc1004697 · Cited by 60
Zapotoczny, B., Szafranska, K., Owczarczyk, K., Kuś, E., Chłopicki, S., & Szymoński, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-08555-0 · Cited by 57
Attacking the genome: emerging siRNA nanocarriers from concept to clinic
Alabi, C. A., Vegas, A. J., & Anderson, D. G. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.05.004 · Cited by 55
Cited by
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Self-citationIn vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Peng, M., Shao, M., Dong, H., Han, X., Hao, M., Yang, Q., Lyu, Q., Tang, D., Shen, Z., Wang, K., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04473-2 · Cited by 22
Metadata
- Authors
- Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 154-155
- Pages
- 79-101
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3036456250
- Cited by
- 264
- References
- 249
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.